VYRIAD
Vyriad is a clinical-stage company developing proprietary oncolytic virus therapies for the treatment of cancers with significant unmet needs. The potentially life-changing oncolytic viral technologies of Vyriad are the result of decades of research by dedicated researchers and clinicians at Mayo Clinic and the University of Miami.
VYRIAD
Industry:
Biotechnology
Founded:
2016-01-01
Address:
Rochester, Minnesota, United States
Country:
United States
Website Url:
http://www.vyriad.com
Total Employee:
51+
Status:
Active
Contact:
507-289-0944
Email Addresses:
[email protected]
Total Funding:
63.38 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving Euro SPF Google Tag Manager WordPress LetsEncrypt SSL By Default Global Site Tag
Similar Organizations
Alpha Biopharma
Alpha Biophama is a clinical stage biopharmaceutical company.
Sio Gene Therapies
Sio Gene Therapies is a clinical-stage biopharmaceutical company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company.
Current Advisors List
Current Employees Featured
Founder
Investors List
Mayo Clinic
Mayo Clinic investment in Series B - Vyriad
Regeneron
Regeneron investment in Series B - Vyriad
Harry H. Stine
Harry H. Stine investment in Series B - Vyriad
Mirae Asset
Mirae Asset investment in Series B - Vyriad
Southeast Minnesota Capital Fund
Southeast Minnesota Capital Fund investment in Series B - Vyriad
Southeast Minnesota Capital Fund
Southeast Minnesota Capital Fund investment in Seed Round - Vyriad
Official Site Inspections
http://www.vyriad.com Semrush global rank: 11.53 M Semrush visits lastest month: 156
- Host name: 151.101.2.159
- IP address: 151.101.2.159
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Vyriad"
Vyriad | Where Therapies Go Viral
At Vyriad, we engineer targeted, efficient and stable virus platforms that bring durable in vivo gene therapies, genome editing, and oncolytic virotherapies to patients.See details»
Our Company - Vyriad
Vyriad is a clinical-stage biotechnology company developing the next generation of targeted genetic therapies in Rochester, Minnesota.See details»
Partnerships | Vyriad
By combining expertise and infrastructure across viral drug delivery, manufacturing and clinical development, Vyriad is built from the ground up to innovate and translate meaningful therapies, and to partner with gene therapy …See details»
Vyriad - Crunchbase Company Profile & Funding
Vyriad is a clinical-stage company developing proprietary oncolytic virus therapies for the treatment of cancers with significant unmet needs. The potentially life-changing oncolytic viral technologies of Vyriad are the result of decades of …See details»
Sodium-Iodide Symporter | Mayo Clinic Business …
Fast forward to 2019 when they launched their second venture, Vyriad, which is a clinical-stage company developing oncolytic virus therapies for the treatment of cancers.See details»
Vyriad - LinkedIn
Vyriad is a clinical-stage biotech company developing targeted genetic therapies that deliver genes directly to cells. | At Vyriad, we are developing the next generation of targeted genetic ...See details»
Vyriad Company Profile 2024: Valuation, Funding
Developer of targeted genetic therapies using engineered viruses, viral vectors, and viral envelope glycoproteins to deliver genes directly to targeted cells.See details»
Vyriad signs 'huge' deal with Novartis to develop new cancer …
Nov 21, 2024 · Vyriad, Rochester’s growing drug development company, signed a “huge” collaboration deal with Novartis to drive its genetic editing technology used to combat cancer …See details»
Our Platforms - Vyriad
We are continuously building on a legacy of excellence, expertise and achievement in viral vector delivery. Our approach to engineering targeted and stable viral delivery solutions has been proven in the clinic with oncolytic viruses.See details»
Vyriad announces strategic collaboration with Novartis to develop …
Nov 20, 2024 · Vyriad, Inc., a clinical-stage biotechnology company developing the next generation of targeted genetic therapies, today announced a strategic collaboration with …See details»
Novartis taps Vyriad’s viral vectors for in vivo T cell editing
Nov 20, 2024 · To develop the next generation of in vivo T cell therapy, Novartis will leverage Vyriad's active targeting lentiviral vector platform to discover and develop new in vivo CAR-T …See details»
Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned …
ROCHESTER, Minn., May 17, 2022 /PRNewswire/ -- Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today …See details»
Our Approach - Vyriad
By combining expertise and infrastructure across viral-based drug development, manufacture and clinical trials, Vyriad is built from the ground up to partner with gene therapy and gene editing …See details»
Vyriad Company Profile - Office Locations, Competitors, Revenue …
See insights on Vyriad including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Leveraging Virus Power To Beat Cancer With Vyriad
Vyriad is developing the next generation of targeted cancer therapies using engineered viruses that selectively attack cancer cells and ignite robust immune responses to prevent cancer …See details»
Vyriad Announces Oral Presentation at the 27th American Society …
May 6, 2024 · Vyriad is a clinical-stage biotechnology company developing the next generation of targeted genetic therapies using engineered viruses, viral vectors and viral envelope …See details»
Regeneron, Vyriad sign deal to develop oncolytic virus-based …
Regeneron has entered into a research collaboration Vyriad to develop new oncolytic (cancer-killing) virus-based treatments for various forms of cancer.See details»
Vyriad announces strategic collaboration with Novartis to develop …
ROCHESTER, Minn., November 20, 2024 — Vyriad, Inc., a clinical-stage biotechnology company developing the next generation of targeted genetic therapies, today announced a strategic …See details»
Vyriad, Inc. (Vyriad, Inc.) - 药物管线_专利_临床试验_投融营收_最新 …
About Vyriad, Inc. Vyriad is a clinical-stage biotechnology company developing the next generation of targeted genetic therapies using engineered viruses, viral vectors and viral …See details»
Press Releases - Vyriad
Aug 15, 2020 · Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced results confirming the activity of …See details»